Treatment and survival study in the C57BL/6J-APC(Min)/+(Min) XXXX with @entity23393 .

@entity5879 @entity1 @entity19 @entity5 @entity23393 @entity1412 @entity1017 @entity652
Our previous studies with the @entity19 model of @entity1412 ( @entity1412 ), C57BL/6J-APC(Min)/+ or Min @entity19 , demonstrated the optimal dose for @entity652 with @entity23393 was 10 mg/kg/day as an undivided dose. Divided doses exhibited no increased efficaciousness. This study examines 10 mg/kg @entity23393 daily (qd) on survival as well as a second daily (q.o.d.) schedule and compares it with sulindac @entity5879 . The q.o.d. schedule at 10 mg/kg was equally efficacious as qd treatment at the same dose. For the q.o.d. group, @entity5 number decreased similarly (p<0.01); while body @entity1017 (p<0.01), hematocrit and average @entity5 area (both, p<0.05) were improved compared with qd treatment. Treatment with @entity23393 (10 mg/kg/day) increased survival significantly (p=0.0004, log-rank) compared to vehicle treated animals. Major biological endpoints (hematocrit, @entity1017 , @entity5 number, average and total area [99% reduction]) were significantly improved in treated animals (p<0.01). Sulindac @entity5879 treatment (50 mg/kg/day) of the Min @entity19 produced no significant biological benefit. The dose schedule study suggests that for @entity5 reduction it is necessary to attain a threshold drug-level but not necessarily sustain it over 24 hrs (pharmacodynamic t1/2 > pharmacokinetic t1/2). During the period of administration @entity23393 dramatically prolongs survival for the @entity19 model of the @entity1 disease, @entity1412 .
